Aridis Pharmaceuticals (ARDS) SEC Filings & 10K Form $0.0003 +0.00 (+50.00%) (As of 11:06 AM ET) Add Compare Share Share SEC Filings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC FilingsTrends Recent Aridis Pharmaceuticals SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel DateFilerForm TypeView06/28/20247:36 PMAridis Pharmaceuticals (Issuer)HAMILTON JOHN F (Reporting)Form 4Statement of changes in beneficial ownership of securities 06/28/20247:36 PMAridis Pharmaceuticals (Issuer)Windham-Bannister Susan Richards (Reporting)Form 4Statement of changes in beneficial ownership of securities 06/28/20246:46 PMAridis Pharmaceuticals (Issuer)Jafri Hasan (Reporting)Form 4Statement of changes in beneficial ownership of securities 06/28/20246:32 PMAridis Pharmaceuticals (Issuer)Patzer Eric (Reporting)Form 4Statement of changes in beneficial ownership of securities 06/28/20246:29 PMAridis Pharmaceuticals (Issuer)Truong Vu (Reporting)Form 4Statement of changes in beneficial ownership of securities 06/27/20243:15 PMAridis Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 02/14/20241:21 PMAridis Pharmaceuticals (Subject)ARMISTICE CAPITAL, LLC (Filed by)Form SC 13G/A02/13/20247:02 PMAridis Pharmaceuticals (Subject)Lind Global Fund II LP (Filed by)Form SC 13G/A01/16/20245:05 AMAridis Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 12/18/20238:40 AMAridis Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 12/18/20238:43 AMAridis Pharmaceuticals (Filer)Form DEFA14A11/06/20233:06 PMAridis Pharmaceuticals (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 11/03/20234:00 PMAridis Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/03/20235:15 AMAridis Pharmaceuticals (Filer)Form DEFA14A(Data available from 1/1/2016 forward) Related Companies and Tools Related Companies Calithera Biosciences 10Q Form Scopus BioPharma 10Q Form Statera Biopharma 10Q Form Comera Life Sciences 10Q Form Genocea Biosciences 10Q Form Genocea Biosciences 10Q Form Evelo Biosciences 10Q Form Ampio Pharmaceuticals 10Q Form eFFECTOR Therapeutics 10Q Form 180 Life Sciences 10Q Form SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NASDAQ:ARDS) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
